You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK):擴大銷售和分銷網絡,即將在中國上市四價季節性流感疫苗
格隆匯 05-24 07:03

格隆匯5月24日丨三葉草生物-B(02197.HK)發佈公吿,公司與科園信海(北京)醫療用品貿易有限公司(“科園貿易”)建立商業合作伙伴關係,科園貿易是中國領先的醫藥進口及分銷企業,為AdimFluS(QIS)的商業上市做準備,此款疫苗是國內目前唯一獲批用於三歲及以上人羣的進口四價季節性流感疫苗。公司預計2023年下半年商業化上市銷售AdimFluS(QIS)。

與科園貿易的合作將支持公司落地其季節性流感疫苗AdimFlu-S(QIS)的商業戰略。科園貿易廣泛的分銷網絡遍佈全國31個省、直轄市及自治區,覆蓋2000多家區縣疾病預防控制中心。科園貿易將補充公司已建立和不斷增長的商業能力,最大化其在中國各地的可及性。

中國的流感疫苗市場以約30%的年複合增長率增長,預計在後大流行時代,隨着疫苗接種意識的提高和政府政策的利好,市場將繼續增長。此外,中國市場的需求使得三價疫苗到四價季節性流感疫苗的轉換持續進行,而四價流感疫苗在2022 年的市場份額已達70%;公司預計,AdimFlu-S(QIS)的銷售額將增加其2023年的收入,併為2024年及以後的增長做出有意義的貢獻。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account